小细胞肺癌二线治疗进展

Advances of second-line therapy for small-cell lung cancer

小细胞肺癌（SCLC）是一种恶性程度较高的肿瘤,一线放化疗非常敏感,但容易复发转移,预后差.SCLC二线治疗进展缓慢,拓扑替康是目前唯一被美国食品和药物管理局批准的二线标准治疗药物.大量关于分子靶向治疗和免疫治疗的研究正在进行中,但大多疗效欠佳.2016年美国临床肿瘤学会年会上公布的靶向Delta样蛋白3的抗体药物耦联物rovalpituzumab tesirine（Rova-T）显示了良好的抗肿瘤活性,似乎为分子靶向治疗带来了新的曙光.

Small cell lung cancer （SCLC） is a highly malignant tumor, which is very sensitive to first-line chemotherapy, but easy to recurrence and metastasis early.So it always has poor prognosis.Second-line therapy for SCLC develops slowly.Topotecan is the only drug approved by US Food and Drug Administration as a second-line chemoradiotherapy.Numerous studies on molecular targeted therapy and immunotherapy are being carried out, but most of them have no or little benefit.Rovalpituzumab tesirine （Rova-T） targeted antibody-drug conjugate （ADC） which is published at the 2016 American Society of Clinical Oncology Annual Meeting shows a good anti-tumor activity, which seems to bring a new dawn of molecular targeted therapy.